title: An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia.
abstract: Essential thrombocythemia (ET) is a risk factor for ischemic stroke and, far more rarely, hemorrhage. We report the case of an untreated 32-year-old woman with a history of JAK2 V617F-positive ET with cerebellar and subarachnoid hemorrhages without evidence of sinus vein thrombosis. She was commenced on oral cytotoxic and antiplatelet therapy. This case report discusses the underlying mechanism of hemorrhagic thrombocythemia and the management dilemma presented by the recommended treatment implications.
authors.affiliation: Department of Neurology, Royal North Shore Hospital, Sydney, Australia; Department of Medicine, University of Sydney, Sydney, Australia. Electronic address: robert.adam@sydney.edu.au.
authors.forename: Robert
authors.initials: R
authors.lastname: Adam
authors.affiliation: Department of Neurology, Royal North Shore Hospital, Sydney, Australia.
authors.forename: Miriam
authors.initials: M
authors.lastname: Priglinger
authors.affiliation: Department of Radiology, Royal North Shore Hospital, Sydney, Australia.
authors.forename: Timothy
authors.initials: T
authors.lastname: Harrington
authors.affiliation: Department of Medicine, University of Sydney, Sydney, Australia.
authors.forename: David
authors.initials: D
authors.lastname: Gottlieb
authors.affiliation: Department of Neurology, Royal North Shore Hospital, Sydney, Australia; Department of Medicine, University of Sydney, Sydney, Australia.
authors.forename: Martin
authors.initials: M
authors.lastname: Krause
mesh_terms: D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D002533:Cerebral Angiography / Q000379:methods; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D020300:Intracranial Hemorrhages / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D053614:Janus Kinase 2 / Q000235:genetics; D008279:Magnetic Resonance Imaging; D009154:Mutation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D013345:Subarachnoid Hemorrhage / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D001241:Aspirin; D006918:Hydroxyurea
keywords: Hemorrhagic stroke; acquired von Willebrand disease; antiplatelet; essential thrombocythaemia; myeloproliferative disorder; young stroke